John Byrnes - Avanos Medical Independent Director
| AVNS Stock | USD 14.77 0.05 0.34% |
Director
Mr. John P. Byrnes serves as Independent Director of the Company. Mr. Byrnes served as the Chairman of the Board of Lincare Holdings, Inc., a provider of home respiratory care, infusion therapy and medical equipment, from March 2000 through March 2015 and as a director of Lincare from May 1997 to August 2015. Mr. Byrnes was the Chief Executive Officer of Lincare from 1997 until March 2015 and served as Lincares President from June 1996 until April 2003. Prior to becoming Lincares President, Mr. Byrnes served in a number of capacities at Lincare over a tenyear period, including serving as Chief Operating Officer throughout 1996. Mr. Byrnes was a director of Kinetic Concepts, Inc., a publiclytraded global medical technology company devoted to the discovery, development, manufacturing and marketing of innovative, hightechnology therapies and products, from January 2003 until February 2011 and of U.S. Renal Care, Inc., a dialysis provider, from August 2005 until 2012. Mr. Byrnes served on the Board of Tenet Healthcare Corporation from November 2016 until May 2018. Mr. Byrnes was selected to serve as a member of our Board of Directors due to his leadership experience as a chief executive officer, knowledge of, and experience in, the healthcare industry, international experience and governance and public company board experience. since 2014.
| Age | 62 |
| Tenure | 11 years |
| Address | 5405 Windward Parkway, Alpharetta, GA, United States, 30004 |
| Phone | 844 428 2667 |
| Web | https://avanos.com |
John Byrnes Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Byrnes against Avanos Medical stock is an integral part of due diligence when investing in Avanos Medical. John Byrnes insider activity provides valuable insight into whether Avanos Medical is net buyers or sellers over its current business cycle. Note, Avanos Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avanos Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Byrnes over three months ago Acquisition by John Byrnes of 7008 shares of Avanos Medical subject to Rule 16b-3 |
Avanos Medical Management Efficiency
The company has return on total asset (ROA) of 0.0197 % which means that it generated a profit of $0.0197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3742) %, meaning that it created substantial loss on money invested by shareholders. Avanos Medical's management efficiency ratios could be used to measure how well Avanos Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.64 in 2025. Return On Capital Employed is likely to gain to -0.38 in 2025. At this time, Avanos Medical's Total Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 446.4 M in 2025, whereas Other Assets are likely to drop slightly above 24.3 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Workman | CONMED | 69 | |
| William Summers | Integer Holdings Corp | 70 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Jeffrey Burbank | Artivion | 58 | |
| Shawn McCormick | Nevro Corp | 56 | |
| Susan Siegel | Nevro Corp | 60 | |
| Michael DeMane | Nevro Corp | 63 | |
| Kristina Wright | Paragon 28 | 47 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Joel Suiter | SurModics | N/A | |
| Brian Concannon | CONMED | 62 | |
| Jerome Lande | CONMED | 45 | |
| Fred Hite | Orthopediatrics Corp | 57 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Cheryl Blanchard | Anika Therapeutics | 61 | |
| David Bronson | CONMED | 67 | |
| Aimee Weisner | Glaukos Corp | 51 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Charles Farkas | CONMED | 68 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | 0.0197 |
Avanos Medical Leadership Team
Elected by the shareholders, the Avanos Medical's board of directors comprises two types of representatives: Avanos Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avanos. The board's role is to monitor Avanos Medical's management team and ensure that shareholders' interests are well served. Avanos Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avanos Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Cato, Vice Resources | ||
| S Mansbach, Senior Vice President Interim General Counsel, Corporate Secretary | ||
| Chip Zimliki, Senior Affairs | ||
| William Haydon, Senior Vice President and General Manager, Pain Management | ||
| Moji James, Senior Vice President General Counsel | ||
| Patrick OLeary, Independent Director | ||
| Sigfrido Delgado, Senior Operations | ||
| Jonathan Turner, VP Officer | ||
| Julie Shimer, Independent Director | ||
| Michelle Scharfenberg, Senior Vice President Chief Ethics and Compliance Officer | ||
| Gary Blackford, Independent Non-Executive Chairman of the Board | ||
| William Hawkins, Independent Director | ||
| David Ball, Senior Vice President - Global Supply Chain and Procurement | ||
| Mojirade James, Senior Vice President General Counsel, Corporate Secretary | ||
| Heidi Kunz, Independent Director | ||
| Lee Burnes, Clinical RD | ||
| Michael Greiner, Chief Financial Officer, Senior Vice President | ||
| Warren Machan, Interim Officer | ||
| Scott Galovan, Senior Development | ||
| Michael CPA, Senior CEO | ||
| Katrine Kubis, Vice Relations | ||
| Sudhakar Varshney, Senior Procurement | ||
| John Byrnes, Independent Director | ||
| Maria Sainz, Independent Director | ||
| Siobhan Smyth, VP Officer | ||
| Vinny Sastri, Senior Quality | ||
| David Crawford, VP Treasurer | ||
| Arjun Sarker, Senior Vice President - International | ||
| John Hurley, Principal Controller | ||
| Kerr Holbrook, Senior Vice President General Manager - Chronic Care | ||
| Joseph Woody, Chief Executive Officer, Director |
Avanos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avanos Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | 0.0197 | ||||
| Profit Margin | (0.57) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 735.53 M | ||||
| Shares Outstanding | 46 M | ||||
| Shares Owned By Insiders | 3.22 % | ||||
| Shares Owned By Institutions | 95.94 % | ||||
| Number Of Shares Shorted | 888.74 K | ||||
| Price To Earning | 51.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Avanos Stock Analysis
When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.